MedTrace Logo

Neoadjuvant Chemotherapy With SEEOX Regimen for Borrmann Type 4 Gastric Cancer

NCT02949258 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2016-10-31

No results posted yet for this study

Summary

Scirrhous gastric cancer, also known as linitis plastic or Borrmann type 4, is an aggressive tumor with an extremely poor prognosis. Aggressive surgical procedures and adjuvant chemotherapies have not improved the survival rate. The purpose of this study is to determine whether neoadjuvant Chemotherapy with SEEOX regimen via intra-arterial and intravenous administration are effective in the treatment of Borrmann type 4 gastric cancer.

Conditions

Interventions

DRUG

oxaliplatin

oxaliplatin 150 mg will be administered from the celiac artery on day 1 of every cycle in all cases

DRUG

etoposide

etoposide 100 mg will be administered from the celiac artery on day 1 of every cycle in all cases

DRUG

epirubicin

epirubicin 30 mg will be administered from the celiac artery on day 1 of every cycle in all cases

DRUG

S1

Oral S-1 120 mg per day will be administered on days 1-14 of every cycle in all cases

Sponsors & Collaborators

  • Jinling Hospital, China

    lead OTHER

Principal Investigators

  • Guoli Li, M.D. · Jinlin Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2019-01-31
Completion
2021-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02949258 on ClinicalTrials.gov